Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Midkine (MDK) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MDK Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View MDK Products |
| Gene Delivery | MDK Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and receptor binding validation. |
View MDK Products |
| Benchmark Ab | Anti-MDK Recombinant Antibody Recombinant positive control derived from clinical benchmark sequences. |
View MDK Products |
| Validator | MDK siRNA Set For target knockdown verification in functional phenotypic assays. |
View MDK Products |
| Related Target A | LRP1 Low-density lipoprotein receptor-related protein 1; key functional receptor mediating MDK-induced migration and survival. |
View LRP1 Products |
| Related Target B | PTN Pleiotrophin; closest homolog to MDK. Essential for off-target selectivity and counter-screening. |
View PTN Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Homology cross-reactivity with Pleiotrophin (PTN) | Human PTN and MDK homolog panel proteins strictly verified by mass spectrometry for cross-screening. |
| Heparin-dependent conformation masking | HEK293 expressed MDK with native glycosylation preserves high-affinity heparin-binding sites. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives | Validated siRNA included for specificity checks |
Live Midkine (MDK) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Midkine (MDK) therapeutics is intensifying, with major players shifting focus from traditional mAbs to multi-specific antibodies and RNA-targeted therapeutics. As first-generation therapies targeting MDK-mediated immunosuppression reach the clinic, the next wave of R&D is targeting the disruption of MDK-receptor axes (such as MDK-LRP1 and MDK-ALK) to overcome resistance to immune checkpoint inhibitors in cold tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Lyra Therapeutics, Propanc Biopharma | Solid Tumors (Pancreatic, NSCLC), Inflammatory Diseases | Receptor Blocking Assay (Need high-purity LRP1 and ALK proteins) |
| RNA Therapeutics (siRNA/ASO) | Academic Institutions, RNAi Biotechs | Glioblastoma, Neuroblastoma | Target Knockdown Validation (Need sequence-verified siRNA sets) |
| CAR-T / Cell Therapy | Translational Research Centers | Advanced Solid Malignancies | Target Specificity & Off-target Screening (Need MDK vs. PTN panel) |